TITLE

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration

AUTHOR(S)
Janssens, A.; Ioannidis, John; Bedrosian, Sara; Boffetta, Paolo; Dolan, Siobhan; Dowling, Nicole; Fortier, Isabel; Freedman, Andrew; Grimshaw, Jeremy; Gulcher, Jeffrey; Gwinn, Marta; Hlatky, Mark; Janes, Holly; Kraft, Peter; Melillo, Stephanie; O'Donnell, Christopher; Pencina, Michael; Ransohoff, David; Schully, Sheri; Seminara, Daniela
PUB. DATE
April 2011
SOURCE
European Journal of Epidemiology;Apr2011, Vol. 26 Issue 4, p313
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis.
ACCESSION #
60411640

 

Related Articles

  • Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Janssens, A.; Ioannidis, John; Duijn, Cornelia; Little, Julian; Khoury, Muin // European Journal of Epidemiology;Apr2011, Vol. 26 Issue 4, p255 

    The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but the quality and...

  • The Evolution of Nonclinical Regulatory Science: Advanced Therapy Medicinal Products as a Paradigm. Vestergaard, Henrik Tang; Apote, Lucia D'; Schneider, Christian K; Herberts, Carla // Molecular Therapy;Sep2013, Vol. 21 Issue 9, p1294 

    Thea authors discuss aspects of nonclinical scientific advice on advanced therapy medicinal products (ATMPs) comprising tissue-engineered products (TEPs), somatic cell therapy medicinal products (CTMPs) and gene therapy medicinal products (GTMPs). The authors provide a comprehensive analysis of...

  • Genome: The Best Is Yet to Come. Agres, Ted // Drug Discovery & Development;Jun2003, Vol. 6 Issue 6, p17 

    Looks at opportunities for drug development opened with the completion of the Human Genome Project. Sequencing of the human genome; Identification of human gene-based targets for therapeutic intervention.

  • PredictABEL: an R package for the assessment of risk prediction models. Kundu, Suman; Aulchenko, Yurii; Duijn, Cornelia; Janssens, A. // European Journal of Epidemiology;Apr2011, Vol. 26 Issue 4, p261 

    The rapid identification of genetic markers for multifactorial diseases from genome-wide association studies is fuelling interest in investigating the predictive ability and health care utility of genetic risk models. Various measures are available for the assessment of risk prediction models,...

  • Ethics in Clinical Research: The Indian Perspective. Sanmukhani, J.; Tripathi, C. B. // Indian Journal of Pharmaceutical Sciences;Mar/Apr2011, Vol. 73 Issue 2, p125 

    Ethics in clinical research focuses largely on identifying and implementing the acceptable conditions for exposure of some individuals to risks and burdens for the benefit of society at large. Ethical guidelines for clinical research were formulated only after discovery of inhumane behavior with...

  • Systems Approaches in Risk Assessment. Lesko, L J; Zheng, S; Schmidt, S // Clinical Pharmacology & Therapeutics;May2013, Vol. 93 Issue 5, p413 

    Adverse drug events (ADEs) remain a universal problem in drug development, regulatory review, and clinical practice with a substantial financial burden on the global health-care system. Recent advances in molecular and 'omics' technologies, along with online databases and bioinformatics, have...

  • Limiting Risk in Bio/Pharmaceutical Development.  // Pharmaceutical Technology;Aug2015, Vol. 39 Issue 8, p50 

    An interview with Mark Stevens, operations director of Gxpi Ltd. which provides enterprise quality management software (EQMS). Topics discussed include patients health risk linked with drug making defects and incorrect labeling and packaging of drugs, need to validate equipments, follow good...

  • Unrequited Love: Reflections on Genomics, as Written in 2032. CAPLAN, ARTHUR L. // GeneWatch;Jan-Feb2012, Vol. 25 Issue 1/2, p13 

    The article presents a scenario for genomics in 2032. The mapping of the human genome in 2000 promising information that would provide instructions for building the human species and information on health risk reportedly proved that genomic risk factor plays only a minor risk in health care....

  • A practical guide to interpretation and clinical application of personal genomic screening. Edelman, Emily; Eng, Charis // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/14/2009, Vol. 339 Issue 7730, p1136 

    The article offers a guide to interpretation and clinical application of personal genomic screening in Great Britain. It defines personal genomic screening as a method of genetic testing that is based on multiple statistical comparisons, or genome-wide associations. Results from genomic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics